SARS-CoV-2 Nucleocapsid Antikörper

Produktnummer ABIN6952432

Zitiert in 12+ Publikationen. Dieser Anti-SARS-CoV-2 Nucleocapsid-Antikörper ist ein Maus-Monoklonal-Antikörper zum Nachweis von SARS-CoV-2 Nucleocapsid in ELISA, WB und IF. Geeignet für SARS Coronavirus-2 (SARS-CoV-2).

Kurzübersicht für SARS-CoV-2 Nucleocapsid Antikörper (ABIN6952432)

Target: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Reaktivität: SARS Coronavirus-2 (SARS-CoV-2)

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser SARS-CoV-2 Nucleocapsid Antikörper ist unkonjugiert

Applikation: ELISA, Western Blotting (WB), Immunofluorescence (IF)

Klon: 3851

Produktdetails anti-SARS-CoV-2 Nucleocapsid Antikörper

Spezifität: Specific for the nucleoprotein of the SARS virus.

Aufreinigung: SARS-CoV-2 (COVID-19, 2019-nCoV) Nucleoprotein antibody is purified from ascites fluid or culture medium by protein A chromoatography or sequential differential precipitations.

Isotyp: IgG2b

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: phosphate saline buffer (0.01M, pH 7.2) containing 0.1 % sodium azide preservative. No stabilizing proteins have been added.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: antibody can be stored at -20°C, stable for one year.

Haltbarkeit: 12 months

Referenzen für anti-SARS-CoV-2 Nucleocapsid Antikörper (ABIN6952432)

Mirabelli, Bragazzi Cunha, Wotring, Sherman, El Saghir, Harder, Kretzler, Sexton, Emmer, Wobus: "ARF6 is a host factor for SARS-CoV-2 infection in vitro." in: The Journal of general virology, Vol. 104, Issue 6, (2023) (PubMed).

Qiao, Wotring, Zhang, Jiang, Xiao, Watt, Gattis, Scandalis, Freier, Zheng, Pretto, Ellison, Swayze, Guo, Sexton, Chinnaiyan: "Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection." in: PloS one, Vol. 18, Issue 2, pp. e0281281, (2023) (PubMed).

Qiao, Wotring, Zheng, Zhang, Zhang, Jiang, Pretto, Eyunni, Parolia, He, Cheng, Cao, Wang, Su, Ellison, Wang, Qin, Yan, Zhou, Ma, Sexton, Chinnaiyan: "Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, Issue 30, pp. e2221809120, (2023) (PubMed).

Wotring, Fursmidt, Ward, Sexton: "Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern." in: Journal of dairy science, (2022) (PubMed).

Sherman, Mirabelli, Tang, Khan, Leix, Kennedy, Graham, Willer, Tai, Sexton, Wobus, Emmer: "Identification of cell type specific ACE2 modifiers by CRISPR screening." in: PLoS pathogens, Vol. 18, Issue 3, pp. e1010377, (2022) (PubMed).

Mirabelli, Sherman, Wotring, El Saghir, Bragazzi Cunha, Harder, Sexton, Emmer, Wobus: "ARF6 is an important host factor for SARS-CoV-2 infection in vitro." in: bioRxiv : the preprint server for biology, (2022) (PubMed).

Wotring, McCarty, Shafiq, Zhang, Nguyen, Meyer, Fursmidt, Mirabelli, Clasby, Wobus, OMeara, Sexton: "In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment." in: bioRxiv : the preprint server for biology, (2022) (PubMed).

Yao, Subedi, Liu, Khalasawi, Pretto-Kernahan, Wotring, Wang, Yin, Jiang, Fu, Dimitrion, Li, Veenstra, Yi, McKinnon, McKinnon, Sexton, Zhou, Mi: "Surface translocation of ACE2 and TMPRSS2 upon TLR4/7/8 activation is required for SARS-CoV-2 infection in circulating monocytes." in: Cell discovery, Vol. 8, Issue 1, pp. 89, (2022) (PubMed).

Wotring, McCarty, Shafiq, Zhang, Nguyen, Meyer, Fursmidt, Mirabelli, Clasby, Wobus, OMeara, Sexton: "In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment." in: Vaccines, Vol. 10, Issue 8, (2022) (PubMed).

Mirabelli, Wotring, Zhang, McCarty, Fursmidt, Pretto, Qiao, Zhang, Frum, Kadambi, Amin, OMeara, Spence, Huang, Alysandratos, Kotton, Handelman, Wobus, Weatherwax, Mashour, OMeara, Chinnaiyan, Sexton: "Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Issue 36, (2021) (PubMed).

Baang, Smith, Mirabelli, Valesano, Manthei, Bachman, Wobus, Adams, Washer, Martin, Lauring: "Prolonged SARS-CoV-2 replication in an immunocompromised patient." in: The Journal of infectious diseases, (2020) (PubMed).

Mirabelli, Wotring, Zhang, McCarty, Fursmidt, Frum, Kadambi, Amin, OMeara, Pretto, Spence, Huang, Alysandratos, Kotton, Handelman, Wobus, Weatherwax, Mashour, OMeara, Sexton: "Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19." in: bioRxiv : the preprint server for biology, (2020) (PubMed).

Details zu SARS-CoV-2 Nucleocapsid

Target: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Andere Bezeichnung: SARS-CoV-2 Nucleocapsid Protein

Substanzklasse: Viral Protein